tiprankstipranks
IMV (IMVIF)
OTHER OTC:IMVIF
Holding IMVIF?
Track your performance easily

IMV (IMVIF) Stock Price & Analysis

355 Followers

IMVIF Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

3.49%96.51%
Insiders
Mutual Funds
3.49% Other Institutional Investors
96.51% Public Companies and
Individual Investors

IMVIF FAQ

What was IMV’s price range in the past 12 months?
IMV lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
    What is IMV’s market cap?
    Currently, no data Available
    When is IMV’s upcoming earnings report date?
    IMV’s upcoming earnings report date is Mar 14, 2024 which is 253 days ago.
      How were IMV’s earnings last quarter?
      Currently, no data Available
      Is IMV overvalued?
      According to Wall Street analysts IMV’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does IMV pay dividends?
        IMV does not currently pay dividends.
        What is IMV’s EPS estimate?
        IMV’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does IMV have?
        IMV has 11,711,637 shares outstanding.
          What happened to IMV’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of IMV?
          Currently, no hedge funds are holding shares in IMVIF
          ---

          IMV Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Company Description

          IMV

          IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
          ---

          IMVIF Company Deck

          ---

          IMVIF Earnings Call

          Q4 2023
          0:00 / 0:00
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          ESSA Pharma
          Gritstone bio
          TRACON Pharmaceuticals
          Oncternal Therapeutics
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis